Literature DB >> 30700320

Correction to: Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.

Kaijian Ling1, Lupin Jiang1, Shi Liang2, Joseph Kwong3, Leiyan Yang1, Yudi Li1, Qingchun Deng4, Zhiqing Liang5.   

Abstract

AbstractThe original article [1] contains errors in Figs. 6 and 8. The corrected figures can be shown ahead.

Entities:  

Year:  2019        PMID: 30700320      PMCID: PMC6352327          DOI: 10.1186/s13048-019-0487-3

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


Correction to: J Ovarian Res (2018) 11:36 https://doi.org/10.1186/s13048-018-0403-2 The original article [1] contains errors in Figs. 6 and 8. The corrected figures can be shown ahead.
Fig. 6

Migratory tendency of GFP (+)/GFP (−) cells when treated with different hormone drugs. a and b) The number of migratory cells increased in the DHT groups of the A2780 + 20 and SKOV3 + 5 GFP (+)/GFP (−) cell lines. c and d) Notably, when treated with DHT, the number of GFP (+) migratory cells increased markedly compared with DMSO or DHT + ASC-J9; e and f) The number of migratory in A2780 + 20 and SKOV3 + 5 Nanog GFP (+) cells were also higher than that of the Nanog GFP (−) cells. For analysis, the cells number in four fields was calculated at 40× magnification. Bar: 100 μM. DHT: 10 nM, and ASC-J9: 5 μM. **P < 0.01; ***P < 0.001

Fig. 8

AR signaling axis enhances the stemness characteristics of ovarian cancer cells. a) Sphere formation assays of the monoclonal GFP (+)/GFP (−) cells of the SKPV3 + 5 and A2780 + 20 cell lines. The sphere formation abilities of the GFP (+) cell lines were significantly stronger than those of the GFP (−) cell lines. Bar: 200 μM. b) Colony formation assays of the monoclonal GFP (+)/GFP (−) cells of the SKPV3 + 5 and A2780 + 20 cell lines. The clonal efficiency of the GFP (+) cells was higher than that of the GFP (−) cells. Bar: 200 μM. c and d) Androgen or inhibitor treatment in SKPV3 + 5 and A2780 + 20 GFP (+) cells. Sphere and colony formation were enhanced when DHT was added, while ASC-J9 decreased this effect. DMSO was used as the vehicle control. DHT: 10 nM, and ASC-J9: 5 μM; Bar: 100 μM. *P < 0.05, **P < 0.01, and ***P < 0.001

Migratory tendency of GFP (+)/GFP (−) cells when treated with different hormone drugs. a and b) The number of migratory cells increased in the DHT groups of the A2780 + 20 and SKOV3 + 5 GFP (+)/GFP (−) cell lines. c and d) Notably, when treated with DHT, the number of GFP (+) migratory cells increased markedly compared with DMSO or DHT + ASC-J9; e and f) The number of migratory in A2780 + 20 and SKOV3 + 5 Nanog GFP (+) cells were also higher than that of the Nanog GFP (−) cells. For analysis, the cells number in four fields was calculated at 40× magnification. Bar: 100 μM. DHT: 10 nM, and ASC-J9: 5 μM. **P < 0.01; ***P < 0.001 AR signaling axis enhances the stemness characteristics of ovarian cancer cells. a) Sphere formation assays of the monoclonal GFP (+)/GFP (−) cells of the SKPV3 + 5 and A2780 + 20 cell lines. The sphere formation abilities of the GFP (+) cell lines were significantly stronger than those of the GFP (−) cell lines. Bar: 200 μM. b) Colony formation assays of the monoclonal GFP (+)/GFP (−) cells of the SKPV3 + 5 and A2780 + 20 cell lines. The clonal efficiency of the GFP (+) cells was higher than that of the GFP (−) cells. Bar: 200 μM. c and d) Androgen or inhibitor treatment in SKPV3 + 5 and A2780 + 20 GFP (+) cells. Sphere and colony formation were enhanced when DHT was added, while ASC-J9 decreased this effect. DMSO was used as the vehicle control. DHT: 10 nM, and ASC-J9: 5 μM; Bar: 100 μM. *P < 0.05, **P < 0.01, and ***P < 0.001
  1 in total

1.  Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.

Authors:  Kaijian Ling; Lupin Jiang; Shi Liang; Joseph Kwong; Leiyan Yang; Yudi Li; Qingchun Deng; Zhiqing Liang
Journal:  J Ovarian Res       Date:  2018-05-02       Impact factor: 4.234

  1 in total
  1 in total

Review 1.  Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.

Authors:  Mohammed Fatih Rasul; Bashdar Mahmud Hussen; Abbas Salihi; Bnar Saleh Ismael; Paywast Jamal Jalal; Anna Zanichelli; Elena Jamali; Aria Baniahmad; Soudeh Ghafouri-Fard; Abbas Basiri; Mohammad Taheri
Journal:  Mol Cancer       Date:  2022-03-03       Impact factor: 27.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.